Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Synairgen ( (GB:SNG) ) just unveiled an announcement.
Synairgen plc announced plans to raise a minimum of £18 million and up to £19 million through fundraising activities, including the issuance of new ordinary shares. The funds will be used to support a Phase 2 trial of SNG001 in mechanically ventilated patients with respiratory viral infections, with the goal of reducing mortality rates and making SNG001 an attractive asset for pharmaceutical partners. This move is seen as a significant step towards advancing the company’s clinical developments and strengthening its market position in respiratory health treatments.
More about Synairgen
Synairgen plc is a company in the respiratory health industry, focusing on the development of SNG001. SNG001 is an investigational inhalation formulation containing the antiviral protein interferon beta, aimed at treating various respiratory viral infections.
YTD Price Performance: -30.69%
Average Trading Volume: 203,733
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £8.4M
For an in-depth examination of SNG stock, go to TipRanks’ Stock Analysis page.
